TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24189215

Group type: EXPERIMENTAL
Intervention: Higher values of tau (τ) indicating slowed V.O2 kinetics
Number of subjects: 85
Study: 21244275

Group type: EXPERIMENTAL
Intervention: FD-APAP (2 × 500 mg tablets)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard acetaminophen (2 × 500 mg tablets)
Number of subjects: 64
Study: 19841453

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 500 microg twice daily for 6 months
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 500 microg twice daily for 30 months
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluticasone, 500 microg twice daily, and salmeterol, 50 microg twice daily for 30 months
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 114
Study: 17558758

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine-based anti-cellulite gel and LED treatments
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo gel and LED treatments
Number of subjects: 9
Study: 15198839

Group type: EXPERIMENTAL
Intervention: Kenalog (triamcinolone acetonide) spray
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cortizone‐10 Quick Shot (hydrocortisone) spray
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no corticosteroid spray)
Number of subjects: 66
Study: 11403522

Group type: EXPERIMENTAL
Intervention: Two 15-minute naps per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Regular schedule for nocturnal sleep
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of scheduled naps and regular bedtimes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (stimulant medications alone)
Number of subjects: 29
Study: 9119854

Group type: EXPERIMENTAL
Intervention: Early tourniquet release before closing the quadriceps layer (group B)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard tourniquet release after wound closure and bandaging (group A)
Number of subjects: 88
Study: 8458044

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg twice a day
Number of subjects: 118

Group type: COMPARATOR
Intervention: Piroxicam 20 mg once a day
Number of subjects: 118
Study: 3023274

Group type: EXPERIMENTAL
Intervention: Nonselective beta-blockade (BB, 80 mg propranolol)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30686697

Group type: EXPERIMENTAL
Intervention: Ringer lactate (RL) for resuscitation and Dextrose Normal Saline (DNS) as maintenance in 1st 72h of burns (Group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ringer lactate (RL) only for 1st 72h (Group B)
Number of subjects: 200
Study: 28057081

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg (RSV)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fimasartan 120 mg (FMS)
Number of subjects: 135
Study: 25950687

Group type: EXPERIMENTAL
Intervention: Blood stool test (BST) compliance
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Colonoscopy use
Number of subjects: 666

Group type: COMPARATOR
Intervention: Colonoscopy use among Haitian households
Number of subjects: 666
Study: 24135513

Group type: EXPERIMENTAL
Intervention: Weight Watchers program (WW)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Self-help condition
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Weight Watchers program (WW) with high usage of all 3 access modes
Number of subjects: 292
Study: 21882156

Group type: EXPERIMENTAL
Intervention: Social reward
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Monetary reward
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group response strategy
Number of subjects: 17
Study: 19697997

Group type: EXPERIMENTAL
Intervention: Mangosteen dietary supplement
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 16705479

Group type: EXPERIMENTAL
Intervention: 8-session Information Support Group Intervention
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 8-session Coping Improvement Group Intervention
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual Care Condition
Number of subjects: 299
Study: 15325833

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study: 11314678

Group type: COMPARATOR
Intervention: MDMA (oral doses ranging from 70-150 mg, 1.35-1.8 mg/kg)
Number of subjects: 74
Study: 9398711

Group type: EXPERIMENTAL
Intervention: Iodine (0.2 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 8492053

Group type: EXPERIMENTAL
Intervention: Sensory Integration Treatment (SIT)
Number of subjects: 96
Study: 3812837

Group type: EXPERIMENTAL
Intervention: Chart reminders
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both chart reminders and nicotine gum
Number of subjects: 162

Group type: COMPARATOR
Intervention: Advice-only group (control)
Number of subjects: 162
Study: 2379381

Group type: EXPERIMENTAL
Intervention: Oral ketanserin 20mg (n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral ketanserin 40mg (n = 8)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin 5mg (n = 4)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ketanserinol production
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peak concentration of ketanserin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Volume of distribution
Number of subjects: 26
Study: 4809462

Group type: EXPERIMENTAL
Intervention: 1 (2 chloroethyl) 3 (4 methylcyclohexyl) 1 nitrosourea (methyl CCNU) at a dosage of 225 mg/sq m p.o. on day 1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Combination program utilizing 5 fluorouracil, cyclophosphamide, and prednisone with or without vincristine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cross over to methyl CCNU after initial treatment failure
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cross over to the combination program after initial treatment failure
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Methyl CCNU
Number of subjects: 43

Group type: COMPARATOR
Intervention: Combination programs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vincristine (part of the combination program)
Number of subjects: 43
Study: 31712893

Group type: EXPERIMENTAL
Intervention: Qingxi black strain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Japanese strain
Number of subjects: 0
Study: 27723955

Group type: EXPERIMENTAL
Intervention: Salt room with halogenerator (treatment group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Salt room without halogenerator (control group)
Number of subjects: 55
Study: 26753646

Group type: EXPERIMENTAL
Intervention: New-pattern obstetrical nursing measures during pregnancy and puerperal period
Number of subjects: 680

Group type: COMPARATOR
Intervention: Traditional nursing measures
Number of subjects: 680
Study: 23408579

Group type: EXPERIMENTAL
Intervention: Face‐to‐face (FTF) clinic
Number of subjects: 295

Group type: COMPARATOR
Intervention: Group conference calls (phone)
Number of subjects: 295
Study: 21575976

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962
Study: 19192459

Group type: EXPERIMENTAL
Intervention: Combination lithium carbonate/nortriptyline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Continuation ECT
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Not applicable (first week after remission)
Number of subjects: 73
Study: 16790661

Group type: COMPARATOR
Intervention: Subgluteal approach
Number of subjects: 56

Group type: COMPARATOR
Intervention: Posterior popliteal approach
Number of subjects: 56
Study: 15066200

Group type: COMPARATOR
Intervention: Outreach intervention by a pharmacist with two visits, providing evidence summary and audit information over a seven-month period.
Number of subjects: 897
Study: 11069320

Group type: EXPERIMENTAL
Intervention: Omeprazole (after 4 days of placebo)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo (first 4 days)
Number of subjects: 301
Study: 9568319

Group type: EXPERIMENTAL
Intervention: Burn blister fluid after thermal injury
Number of subjects: 11
Study: 8095573

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 65
Study: 3781336

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31663368

Group type: EXPERIMENTAL
Intervention: Early ART initiators (CD4 >500 cells/mm3)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Late ART initiators (CD4 <200 cells/mm3)
Number of subjects: 390
Study: 30032945

Group type: EXPERIMENTAL
Intervention: NIATx200 quality improvement intervention
Number of subjects: 121
Study: 27544129

Group type: EXPERIMENTAL
Intervention: Patients with any SPARC expression (n=35)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients without SPARC expression (n=15)
Number of subjects: 50
Study: 25400507

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 626

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 626
Study: 23739633

Group type: EXPERIMENTAL
Intervention: High-flow oxygen (HFO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP)
Number of subjects: 30
Study: 20508529

Group type: EXPERIMENTAL
Intervention: Automated telephone intervention
Number of subjects: 5905

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 5905
Study: 18455084

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16649891

Group type: EXPERIMENTAL
Intervention: Radial shock-wave therapy (RSWT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Less active similar therapy (Control)
Number of subjects: 90
Study: 12468784

Group type: EXPERIMENTAL
Intervention: Direct percutaneous transluminal angioplasty (PTA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 70
Study: 9486920

Group type: EXPERIMENTAL
Intervention: 2-Chlorodeoxyadenosine (2-CdA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 2-Chlorodeoxyadenosine (2-CdA) + daunorubicin (DNR)
Number of subjects: 19
Study: 7619662

Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.15, 0.3 and 0.6 micrograms kg‐1 i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-365,260 (10 mg, 50 mg p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentagastrin (0.3 micrograms kg‐1 i.v.)
Number of subjects: 0
Study: 2793453

Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg every 8 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 888714

Group type: EXPERIMENTAL
Intervention: Eccentric contractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentric contractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31860521

Group type: EXPERIMENTAL
Intervention: Foveal sparing ILM peeling
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard ILM peeling (control group)
Number of subjects: 34
Study: 31102318

Group type: EXPERIMENTAL
Intervention: Low WWC1 expression
Number of subjects: 470

Group type: COMPARATOR
Intervention: High WWC1 expression
Number of subjects: 470
Study: 29853785

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 26894822

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25447269

Group type: EXPERIMENTAL
Intervention: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% (once daily)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Timolol 0.5% (twice daily)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Tafluprost 0.0015% (once daily)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 564

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 564
Study: 22114059

Group type: EXPERIMENTAL
Intervention: Combined Therapy (CT) applied once a week (G1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined Therapy (CT) applied twice a week (G2)
Number of subjects: 50
Study: 19922664

Group type: EXPERIMENTAL
Intervention: HIV-1 infected adults
Number of subjects: 339

Group type: COMPARATOR
Intervention: HIV-1 uninfected adults
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: HIV-1 infected and uninfected adults
Number of subjects: 339
Study: 17980977

Group type: EXPERIMENTAL
Intervention: 15 mg/kg sodium nitrate for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 20
Study: 16354890

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Progestin‐only pill
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 162

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 162
Study: 11942868

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 2 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular ketoprofen 2 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (intramuscular)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (both intravenous and intramuscular)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular ketoprofen
Number of subjects: 120
Study: 9794747

Group type: EXPERIMENTAL
Intervention: 2.5 mg bendrofluazide daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 1.25 mg bendrofluazide daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 2.5 mg bendrofluazide every other day
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 15374200

Group type: EXPERIMENTAL
Intervention: standardised ginseng‐containing vitamin complex
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 2633288

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 100
Study: 876437

Group type: EXPERIMENTAL
Intervention: Single oral dose of amoxycillin (3 g for adults and 100 mg/kg for children)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Single dose of amoxycillin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Single-dose therapy
Number of subjects: 31
Study: 31441437

Group type: EXPERIMENTAL
Intervention: Medium chain triglyceride‐Olive‐Fish‐Soy lipid emulsion (MOFS‐LE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soybean oil‐based lipid emulsion (S‐LE)
Number of subjects: 40
Study: 27782976

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) using oral magnesium citrate
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sodium phosphate (NaP) enema alone
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study: 25565485

Group type: EXPERIMENTAL
Intervention: 3 g of fish oil (240 mg EPA + 240 mg DHA) with a multivitamin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 6 g of fish oil (480 mg EPA + 480 mg DHA) with a multivitamin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 6 g of fish oil without a multivitamin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 23831445

Group type: EXPERIMENTAL
Intervention: Heparin-bonded covered stents (Viabahn)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 141
Study: 21411235

Group type: EXPERIMENTAL
Intervention: Integrated treatment for comorbid SUD and PTSD
Number of subjects: 102
Study: 19286192

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/day)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 17553671

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) and Lamotrigine (LTG)
Number of subjects: 225
Study: 15334286

Group type: EXPERIMENTAL
Intervention: 10 microgrammes recombinant hepatitis B vaccine
Number of subjects: 92

Group type: COMPARATOR
Intervention: 20 microgrammes recombinant hepatitis B vaccine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 92
Study: 11486448

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study: 9710861

Group type: EXPERIMENTAL
Intervention: Peak VO2
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Optimal cut point of 18.3 mL.kg-1.min-1
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: VO2 < 18 mL.kg-1.min-1
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Peak VO2 included in PF model
Number of subjects: 161
Study: 1836989

Group type: EXPERIMENTAL
Intervention: 26 G spinal needle
Number of subjects: 284

Group type: COMPARATOR
Intervention: 22 G spinal needle
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: 4.5 g iodine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Operator experience
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid leakage
Number of subjects: 284
Study: 7035046

Group type: EXPERIMENTAL
Intervention: Colostrum feeding
Number of subjects: 180

Group type: COMPARATOR
Intervention: Glucose water feeding
Number of subjects: 180
Study: 30894408

Group type: EXPERIMENTAL
Intervention: Telephone-based developmental screening and care coordination through 2-1-1
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 152
Study: 27838447

Group type: EXPERIMENTAL
Intervention: Anodal-tDCS (a-tDCS) targeting the left dorsolateral prefrontal cortex (DLPFC) for 20 minutes at 2mA current intensity
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham-tDCS (placebo) with the same electrode position but stimulator turned off after 30 seconds
Number of subjects: 17
Study: 26699739

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-fentanyl (DF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam-fentanyl (MF)
Number of subjects: 60
Study: 24332248

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LD ASA)
Number of subjects: 23336

Group type: COMPARATOR
Intervention: High-dose aspirin (HD ASA)
Number of subjects: 23336

Group type: COMPARATOR
Intervention: Study site variability
Number of subjects: 23336

Group type: COMPARATOR
Intervention: Median odds ratio comparing sites
Number of subjects: 23336
Study: 22613433

Group type: EXPERIMENTAL
Intervention: Transumbilical single‐port laparoscopic hysterectomy (TSPLH)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Traditional four‐port total laparoscopic hysterectomy (TLH)
Number of subjects: 108
Study: 20105036

Group type: EXPERIMENTAL
Intervention: 4 weeks of Integrative Body‐Mind Training (IBMT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 35
Study: 18700219

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Structured care
Number of subjects: 150
Study: 15972866

Group type: EXPERIMENTAL
Intervention: ChAglyCD3
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12870262

Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (up to 45 mmHg, Group I, n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intervention to ensure mild hypocapnia (around 33 mmHg, Group II, n = 16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 10231869

Group type: EXPERIMENTAL
Intervention: Combination of growth hormone (GH) and low-dose estrogen (ethinyl estradiol, 5 micrograms/d) in girls with Turner syndrome.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Growth hormone (GH) alone in girls with Turner syndrome.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Estrogen (ethinyl estradiol, 50 micrograms/d) and progesterone in adult females with Turner syndrome.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Growth hormone (GH) alone in adults with Turner syndrome.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol, 50 micrograms/d) and progesterone in combination with GH in adults.
Number of subjects: 11
Study: 9193221

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and fluorouracil) plus radiation therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: p53 immunohistochemistry
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: p53 mutations
Number of subjects: 44
Study: 1493838

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3554553

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg in 5 ml saline, repeated on demand)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intramuscular morphine (10 mg on request)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 33
Study: 30149366

Group type: EXPERIMENTAL
Intervention: nab‐paclitaxel, gemcitabine, cisplatin and oral capecitabine (PAXG; arm A; N = 26)
Number of subjects: 54

Group type: COMPARATOR
Intervention: nab‐paclitaxel followed by gemcitabine (AG; arm B; N = 28)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: PAXG
Number of subjects: 54

Group type: COMPARATOR
Intervention: AG
Number of subjects: 54
Study: 27936949

Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Valsartan (ARB)
Number of subjects: 76
Study: 25471910

Group type: COMPARATOR
Intervention: No brace
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft brace
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rigid brace
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60